We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Issues Draft Guidance on Biovailability Trials
FDA Issues Draft Guidance on Biovailability Trials
Sponsors of bioavailability trials should be prepared to show that any differences in the rate or extent of absorption compared with an existing drug won’t affect the safety or efficacy of the candidate drug, the FDA said in a new draft guidance issued Monday.